Case report of Hepatitis C treatment during pregnancy-Reference-Cited by-同舟云学术

Case report of Hepatitis C treatment during pregnancy

Published:2023-11-08 Issue:2 Volume:14 Page:39-42
ISSN:2582-0249
Container-title:Journal of Case Reports and Images in Obstetrics and Gynecology
language:en
Short-container-title:J Case Rep Images Obstet Gynecol

Author:

Bock Kirsten¹,Atkinson Andrea²,Elwood Chelsea³,Ramji Alnoor⁴

Affiliation:

1. Resident Physician within the UBC Department of Obstetrics and Gynaecology, Room C342, 4500 Oak Street, Vancouver, BC V6H 3N1, Canada

2. Reproductive Infectious Diseases Fellow, Faculty of Medicine, Obstetrics and Gynaecology, University of British Columbia, Room C342, 4500 Oak Street, Vancouver, BC V6H 3N1, Canada

3. Clinical Assistant Professor, Division of Gynaecologic Specialties, Faculty of Medicine, Obstetrics and Gynaecology, University of British Columbia, 915-750 West Broadway, Vancouver, BC V5Z 1H8, Canada

4. Clinical Associate Professor, Department of Gastroenterology, St. Paul’s Hospital, University of British Columbia, 770-1190 Hornby Street, Vancouver, BC V6Z 3C7, Canada

Abstract

Introduction: Despite the increasing availability of Hepatitis C (HCV) anti-viral therapy for adults, there is minimal data regarding treatment safety and efficacy during pregnancy. Case Report: A 33-year-old primiparous female underwent successful HCV treatment with direct-acting antivirals (DAAs) beginning at 26 weeks gestational age. Conclusion: This case demonstrates the effective treatment of HCV during pregnancy. Formal trials are still required to assess the long-term safety and efficacy as treatment with DAAs for Hepatitis C is not yet established in pregnancy.

Publisher

Edorium Journals Pvt. Ltd.

Reference7 articles.

1. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: Systematic review and meta-analysis. Clin Infect Dis 2014;59(6):765–73.

2. Chappell CA, Scarsi KK, Kirby BJ, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: A phase 1 pharmacokinetic study. Lancet Microbe 2020;1(5):e200–8.

3. Jhaveri R, Yee LM, Antala S, Murphy M, Grobman WA, Shah SK. Responsible inclusion of pregnant individuals in eradicating HCV. Hepatology 2021;74(3):1645–51.

4. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. World Health Organization. 2016. [Available at: https://apps.who.int/iris/handle/10665/246177]

5. Pedrana A, Munari S, Stoové M, Doyle J, Hellard M. The phases of hepatitis C elimination: Achieving WHO elimination targets. Lancet Gastroenterol Hepatol 2021;6(1):6–8.